Registreer u om meldingen in te stellen voor instrumenten, economische gebeurtenissen en artikelen van de auteurs die u volgt.
Gratis registreren Heeft u al een account? Inloggen
Dennis de Boer
13.08.2021 19:55
The market for diabetic care is growing fast and if SENS can get FDA approval to extend the life of every implant, it will help increase the product’s adoption. The sales are low and the near-term earnings don’t justify the valuations right now. However, the successful commercialization of Eversense could take SENS stock much higher.Thanks to the stock sales earlier in 2021, Senseonics has enough cash to grow its business as it works to commercialize Eversense.
1
0
